{"created":"2023-05-15T14:52:20.975084+00:00","id":71474,"links":{},"metadata":{"_buckets":{"deposit":"2557a464-d84f-408d-901b-788fbfb3b1c6"},"_deposit":{"created_by":1,"id":"71474","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"71474"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00071474","sets":["10:28"]},"author_link":["702792","702785","702784","702789","702787","702790","702782","702783","702794","702795","702791","702788","702793","702786"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2014-06-09","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives: The aim of the present study was to evaluate the clinical value of PET/CT with FAZA, a PET probe for tumor hypoxia, for advanced lung cancer patients, in comparison to FDG-PET/CT.\n\\nMethods: Thirty four patients with non-small cell lung cancer (stage III and IV) received PET/CT with FAZA and FDG. After treatment, patients were followed to evaluate the treatment response and survival. Overall-, progression-free survival, local control and control of LN metastases were compared with uptake parameters of FAZA (tumor-muscle ratio at 2h (T/M)) and FDG (SUVmax at 1h (SUV)). Study protocol was approved by the institutional review board, and informed consent was obtained from all patients.\n\\nResults: There was a weak correlation between FAZA T/M and FDG SUV of primary lesion, but intra-tumoral distribution patterns were not identical. Stage IV patients tended to show worse overall- and progression-free survival than stage III patients (p=0.122 and 0.124, respectively). Although not statistically significant, mean FAZA T/M of primary lesion tended to be higher in non-survivors and in patients with disease progression, whereas such tendency was not observed for mean FDG SUV. Furthermore, patients with FAZA T/M > 2.245 showed significantly worse progression-free survival (p=0.028). Patients who developed local recurrence showed significantly higher mean FAZA T/M (p=0.009) of primary lesion than who did not. In contrast, significantly higher mean FDG SUV of LN metastasis was observed in patients who developed recurrence in LN metastasis (p = 0.043). Mean FAZA T/M of LN metastasis was also higher in patients who developed LN recurrence (p = 0.070). \n\\nConclusion: PET/CT with FAZA may have a potential for the prediction of disease control and survival of advanced lung cancer patients.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"SNMMI 2014 Annual meeting ","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"702782","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Inubushi, Masayuki"}],"nameIdentifiers":[{"nameIdentifier":"702783","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Koizumi, Mitsuru"}],"nameIdentifiers":[{"nameIdentifier":"702784","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshikawa, Kyosan"}],"nameIdentifiers":[{"nameIdentifier":"702785","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong"}],"nameIdentifiers":[{"nameIdentifier":"702786","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Horiike, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"702787","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kudo, Keita"}],"nameIdentifiers":[{"nameIdentifier":"702788","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ohyanagi, Fumiyoshi"}],"nameIdentifiers":[{"nameIdentifier":"702789","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nishio, Makoto"}],"nameIdentifiers":[{"nameIdentifier":"702790","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀 恒夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"702791","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"犬伏 正幸","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"702792","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小泉 満","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"702793","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉川 京燦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"702794","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"張 明栄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"702795","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients."}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-06-20"},"publish_date":"2014-06-20","publish_status":"0","recid":"71474","relation_version_is_last":true,"title":["Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:50:50.336975+00:00"}